Emi H. Caywood, MD

Hematology/Oncology

Primary Office

Nemours Children's Hospital, Delaware Nemours Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803 Appointment: (800) 416-4441

Other Offices

Get to Know Me

With a passion for science and my desire to always work with people, I decided to pursue becoming a doctor after college. Today, I’m incredibly fortunate to help treat children with a variety of cancers and blood disorders – including eye tumors.

Why I Treat Children

I’m amazed by their resilience, honesty and innocence – and I want to help make their life the best it can possibly be The children I treat didn’t ask for the medical conditions they have, and they deserve the best that is in me.

Education & Training

Fellowship

  • Pediatric Hematology/Oncology - Johns Hopkins University, 2009

Residency

  • Pediatrics - Georgetown University Hospital (MedStar Health), 2005

Medical/Dental School

  • MD - University of Medicine and Dentistry of New Jersey, 2002

Board Certifications

  • American Board of Pediatrics/Pediatric Hematology-Oncology

Awards & Recognition

  • 2014 Delaware Today magazine, Top Doctors
  • 2013 Hyundai Hope on Wheels Grant Scholar
  • 2008 Fellow Award Finalist, American Society of Hematology

Insurance Accepted

  • Aetna Better Health PA Kids HMO
  • Aetna HMO
  • Aetna PPO/POS/EPO
  • Amerihealth Caritas DE - PENNSYLVANIA SPECIALISTS ONLY
  • Amerihealth Caritas Delaware
  • Carefirst MD Community Health Plan Mcaid
  • Cigna/Great West HMO EPO POS
  • Cigna/Great West PPO
  • Delaware First Health
  • Delaware Medicaid/Diamond State
  • Delaware Medicare
  • Devon Health Services
  • Fidelis Care NJ Medicaid HMO
  • First Health/Affordable PPO
  • Geisinger Health Plan Commercial
  • Global Medical Managment DE/PA
  • Health Partners Medicaid/Kidz Partner HMO
  • Highmark Blue Cross Blue Shield of Delaware
  • Highmark Blue Cross Blue Shield of Pennsylvania
  • Highmark Medicaid Health Options
  • Horizon Blue Cross Blue Shield of New Jersey
  • Independance Blue Cross/Amerihealth/Keystone Health Plan
  • Insurance Administrators of America
  • INTEGRA Administrative Group (ClaimsBridge)
  • Interlink Transplant
  • Keystone First Medicaid HMO
  • Lifetrac Transplant
  • Maryland Medicaid
  • Multiplan PPO
  • New Jersey Medicaid
  • Pennsylvania Medicaid
  • Plan Vista/NPPN PPO
  • Preferred Healthcare PPO
  • Private Health Care Systems (PHCS)
  • Qualcare HMO/POS/PPO
  • Star Healthcare Network
  • Three Rivers Provider Network
  • Tricare/Humana Military Health Services
  • United Healthcare of the Mid-Atlantic
  • UPMC MCAID/CHIP PA DE
  • US Family Health Plan
  • Wellpoint Maryland Medcaid

  • Anemia
  • Blood and Bone Marrow Transplantation
  • Blood Disorders
  • Cancer Care
  • Leukemia
  • Lymphoma
  • Neuroblastoma
  • Neutropenia
  • Retinoblastoma

Medical Interests

  • Acute myeloid leukemia (AML)

  • Subburaj, D., Ng, B., Kariminia, A., Abdossamadi, S., Lauener, M., Nemecek, E. R., & Schultz, K. R. (2022). Metabolomic identification of alpha-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease. Blood, 139(2), 287-299. doi:10.1182/blood.2021013244

    View Full Publication
  • Getz, K. D., Szymczak, J. E., Li, Y., Madding, R., Huang, Y.-S. V., Aftandilian, C., & Aplenc, R. (2021). Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 4(10). doi:10.1001/jamanetworkopen.2021.28385

    View Full Publication
  • Schultz, K. R., Kariminia, A., Ng, B., Abdossamadi, S., Lauener, M., Nemecek, E. R., & Cuvelier, G. D. E. (2020). Immune profile differences between chronic GVHD and late acute GVHD: Results of the ABLE/PBMTC 1202 studies. Blood, 135(15), 1287-1298. doi:10.1182/BLOOD.2019003186

    View Full Publication
  • Chan, A. Y., Leiding, J. W., Liu, X., Logan, B. R., Burroughs, L. M., Allenspach, E. J., & Torgerson, T. R. (2020). Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 11. doi:10.3389/fimmu.2020.00239

    View Full Publication
  • Dvorak, C. C., Haddad, E., Buckley, R. H., Cowan, M. J., Logan, B., Griffith, L. M., & Puck, J. M. (2019). The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 143(1), 405-407. doi:10.1016/j.jaci.2018.08.027

    View Full Publication
  • Cuvelier, G. D. E., Nemecek, E. R., Wahlstrom, J. T., Kitko, C. L., Lewis, V. A., Schechter, T., & Schultz, K. R. (2019). Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood, 134(3), 304-316. doi:10.1182/blood.2019000216

    View Full Publication
  • Shields, C. L., Say, E. A. T., Pefkianaki, M., Regillo, C. D., Caywood, E. H., Jabbour, P. M., & Shields, J. A. (2017). RHEGMATOGENOUS RETINAL DETACHMENT after INTRAARTERIAL CHEMOTHERAPY for RETINOBLASTOMA: The 2016 Founders Award Lecture. Retina, 37(8), 1441-1450. doi:10.1097/IAE.0000000000001382

    View Full Publication
  • Shields, C. L., Alset, A. E., Say, E. A. T., Caywood, E., Jabbour, P., & Shields, J. A. (2016). Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. Journal of Pediatric Ophthalmology and Strabismus, 53(5), 275-284. doi:10.3928/01913913-20160719-04

    View Full Publication
  • Shields, C. L., Jorge, R., Say, E. A. T., Magrath, G., Alset, A., Caywood, E., & Shields, J. A. (2016). Unilateral retinoblastoma managed with intravenous chemotherapy versus intra-arterial chemotherapy. Outcomes based on the international classification of retinoblastoma. Asia-Pacific Journal of Ophthalmology, 5(2), 97-103. doi:10.1097/APO.0000000000000172

    View Full Publication
  • Lewen, M., Gresh, R., Queenan, M., Paessler, M., Pillai, V., Hexner, E., & Wertheim, G. (2016). Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: A case report. Biomarker Research, 4(1). doi:10.1186/s40364-016-0069-0

  • Caywood, E. H., & Kolb, E. A. (2015). Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials. Journal of Clinical Oncology, 33(36), 4238-4239. doi:10.1200/JCO.2015.63.9252

    View Full Publication
  • Hossain, M. J., Xie, L., & Caywood, E. H. (2015). Prognostic factors of childhood and adolescent acute myeloid leukemia (AML) survival: Evidence from four decades of US population data. Cancer Epidemiology, 39(5), 720-726. doi:10.1016/j.canep.2015.06.009

    View Full Publication

  • English